CML HealthCare to Offer Mitomics Prostate Test in Canada | GenomeWeb

NEW YORK (GenomeWeb News) – CML HealthCare today said that it has licensed exclusive rights to offer Mitomics' prostate cancer test in Canada.

The Prostate Core Mitomic Test is a mitochondrial DNA-based test that detects malignant cells in biopsy tissue. The firms said it can detect mitochondrial DNA alterations in benign tissue when a tumor is present in adjacent tissue, and they noted that the test offers 85 percent sensitivity with a negative predictive value of 92 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.

In Science this week: new chromatin imaging approach, and more.